Vapotherm is set to debut its Access365 home ventilator to enhance the quality of life for patients with late-stage hypercapnic chronic obstructive pulmonary disease (COPD).

The device helps in reducing hospital readmissions and healthcare equipment (HME) costs.

It integrates various advanced features, including ventilation-assured pressure support (VAPS) and volume control/assist ventilation modes, alongside Vapotherm’s established high-velocity therapy.

A medical-grade humidifier is built into the device, which also has integrated Bluetooth-enabled pulse oximetry and spirometry.

Furthermore, the Access365 Home Ventilation Solution offers cloud connectivity, facilitating remote data access and system updates.

It also features a patient engagement platform designed to interrupt the cycle of symptom exacerbation and hospital readmission by enabling the early detection of deteriorating symptoms, thus allowing for quick clinical responses.

Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free
sample

Your download email will arrive shortly

We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form

By GlobalData







Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vapotherm chief medical officer Dr Jessica Whittle said: “Our mission is to improve quality of life and reduce hospital readmissions for patients who struggle with respiratory disease.

“Access365 will provide optimal treatment at home, especially for COPD patients, by combining the known benefits of nocturnal NIV [non-invasive ventilation] with the comfort of high-velocity therapy for daytime use.”

Vapotherm anticipates that the home ventilator will receive clearance from the US Food and Drug Administration in early 2025.

Vapotherm president and CEO Joe Army said: “Vapotherm is committed to supporting patients both in and out of the hospital. The recently announced discontinuation of Philips Respironics home ventilators in the US highlights a potential concern for patients and HMEs alike but also a unique opportunity for Vapotherm.

“We are excited to be able to provide newer and more comprehensive options for these patients and the HMEs that support them.”

The device is planned to be unveiled at the MEDTRADE conference in Dallas, US, on 27 March 2024.

Last month, Vapotherm received regulatory approval for its high-velocity therapy (HVT) 2.0 system in Brazil.


Source link